Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-019843
Filing Date
2022-05-12
Accepted
2022-05-12 16:04:19
Documents
74
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q scyx-10q_20220331.htm   iXBRL 10-Q 2009676
2 EX-10.1 scyx-ex101_26.htm EX-10.1 355389
3 EX-31.1 scyx-ex311_8.htm EX-31.1 18617
4 EX-31.2 scyx-ex312_7.htm EX-31.2 19284
5 EX-32.1 scyx-ex321_6.htm EX-32.1 9445
  Complete submission text file 0001564590-22-019843.txt   10061678

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA scyx-20220331.xsd EX-101.SCH 62716
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE scyx-20220331_cal.xml EX-101.CAL 57961
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE scyx-20220331_def.xml EX-101.DEF 225492
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE scyx-20220331_lab.xml EX-101.LAB 509668
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scyx-20220331_pre.xml EX-101.PRE 396011
68 EXTRACTED XBRL INSTANCE DOCUMENT scyx-10q_20220331_htm.xml XML 2174081
Mailing Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548
Business Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 201-884-5485
SCYNEXIS INC (Filer) CIK: 0001178253 (see all company filings)

EIN.: 562181648 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36365 | Film No.: 22917708
SIC: 2834 Pharmaceutical Preparations